CV 9103

Drug Profile

CV 9103

Alternative Names: CV9103; mRNA prostate cancer vaccine - CureVac

Latest Information Update: 04 Oct 2015

Price : $50

At a glance

  • Originator CureVac
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 04 Oct 2015 No recent reports of development identified - Phase-II for Prostate cancer (Hormone refractory, Metastatic disease) in Italy and Germany (Intradermal)
  • 04 Oct 2015 No recent reports of development identified - Phase-I for Prostate cancer (Hormone refractory, Metastatic disease) in USA (Intradermal)
  • 07 Jul 2015 Updated adverse events and immunogenicity data from a phase I/IIa study in Prostate cancer published in the Journal for ImmunoTherapy of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top